반응식
[OH-].[Na+].[OH:3][NH:4][C:5](N)=[O:6].Br[CH:9]([CH:14](Br)[CH2:15][CH:16]([NH:21][C:22]1[C:27]([F:28])=[CH:26][N:25]=[C:24]([C:29]2[C:37]3[C:32](=[N:33][CH:34]=[C:35]([F:38])[CH:36]=3)[NH:31][CH:30]=2)[N:23]=1)[C:17]([CH3:20])([CH3:19])[CH3:18])C(OC)=O.CC(O)=O>O.CO>[F:28][C:27]1[C:22]([NH:21][CH:16]([C:17]([CH3:20])([CH3:19])[CH3:18])[CH2:15][C:14]2[O:3][N:4]=[C:5]([OH:6])[CH:9]=2)=[N:23][C:24]([C:29]2[C:37]3[C:32](=[N:33][CH:34]=[C:35]([F:38])[CH:36]=3)[NH:31][CH:30]=2)=[N:25][CH:26]=1참가 물질
실험 절차
To a solution of NaOH (0.015 g) dissolved in water (0.410 mL) was added hydroxyurea (0.008 g, 0.100 mmol). The resulting mixture was stirred for 30 minutes before the dropwise addition of methyl 2,3-dibromo-5-((5-fluoro-2-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl)amino)-6,6-dimethylheptanoate, 85a, (0.064 g, 0.110 mmol) in MeOH (0.150 mL). The solution was stirred for 6 hours before the addition of AcOH (0.031 mL). The residue was purified by reverse phase preparative HPLC to afford the desired product: 1H NMR (300 MHz, MeOD) δ 8.57 (dd, J=9.7, 2.8 Hz, 1H), 8.16 (d, J=5.5 Hz, 2H), 8.00 (d, J=4.1 Hz, 1H), 5.68 (s, 1H), 3.03 (ddd, J=27.4, 15.4, 12.3 Hz, 2H), 1.10 (d, J=3.3 Hz, 11H); LCMS Gradient 10-90%, 0.1% formic acid, 5 minutes, C18/ACN, RT=2.15 minutes (M+H) 416.04.
후처리
- customThe residue was purified by reverse phase preparative HPLC
출처 및 근거
- ORD 기록
- ord-1c44517c02f44aa592d5f8ced502462f
- 출처 데이터셋
- uspto-grants-2016_07
- 특허 번호
- US09394302B2
연결된 노트
불러오는 중…